ANCA-asszociált vasculitis: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 30
• BCMA 14
• CD20 2
• AKT 0
• CTLA-4 0
• CD38 1
• IL-15 1
• IL-4 0
• mTOR 0
• PI3K 0
• SGLT2 1
• STAT3 0
• VEGF 0

297 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · F30

  Regulation of type I interferon signaling by A20 (TNFAIP3) in autoimmune and autoinflammatory disease

  University of Pittsburgh at Pittsburgh· Pittsburgh, Egyesült Államok· 55 114 USD awarded in fiscal year 2026· until 2029. okt.

• NIH NCCIH · R34

  Virtual Rheum: The Development of a Virtual Mind-Body Resiliency Intervention for Patients with ANCA-Associated Vasculitis and Systemic Lupus Erythematosus

  Massachusetts General Hospital· Boston, Egyesült Államok· 770 399 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NHLBI · R01

  Cell-free RNA signature for Diagnosis and Personalized Therapeutics in Children with Kawasaki Disease

  University of California, San Diego· La Jolla, Egyesült Államok· 1 639 166 USD awarded in fiscal year 2026· until 2028. jún.

• NIH NIAID · R01

  Gastrointestinal tissue-adapted eosinophils in health and disease

  University of Colorado Denver· Aurora, Egyesült Államok· 771 983 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NIAID · R56

  Investigation of human immune responses in acute rickettsioses: towards development of host response-based diagnostics

  Duke University· Durham, Egyesült Államok· 807 481 USD awarded in fiscal year 2026· until 2027. aug.

• European Commission (Horizon Europe) · HORIZON-CSA

  TwinDEEPS – Twinning deep-ocean exploration and observation capacity for sustainable development

  Centro Interdisciplinar de Investigacao Marinha e Ambiental· Matosinhos, Portugália· EU contribution 1 498 973 EUR· until 2027. jún.· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Mucosal Breaks of Bacteria Trigger Pathogenic B-cell Responses in ANCA-associated Vasculitis (Breaking ANCA)

  Academisch Ziekenhuis Leiden· Leiden, Hollandia· EU contribution 296 296 EUR· until 2028. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  EXPanding AAV gene therapy by EDITing (EXPEDITE)

  Fondazione Telethon Ets· Roma, Olaszország· EU contribution 2 492 303 EUR· until 2028. okt.

• European Commission (Horizon Europe) · HORIZON-RIA

  Preclinical development of a 3rd-generation interleukin-2 targeted to inflammatory sites (TiilT)

  Sorbonne Universite· Paris, Franciaország· EU contribution 5 605 576 EUR· until 2028. máj.· 6 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  Next-generation AAV vectors for liver-directed gene therapy (AAVolution)

  Fondazione Telethon Ets· Roma, Olaszország· EU contribution 4 500 000 EUR· until 2027. szept.· 5 countries

10 of 72 running projects, newest first. Listed amounts together: 35,5 M USD + 14,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

  NCT06508346· The Children's Hospital of Zhejiang University School of Medicine· Frissítve: 2026. jún. 16.

  “no participants enrolled”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  PR3-AAV Resilient Remission or PRRR

  NCT05376319· Mayo Clinic· Frissítve: 2026. máj. 6.

  “Funding was withdrawn by sponsor.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Hydroxychloroquine in ANCA Vasculitis Evaluation

  NCT04316494· Guy's and St Thomas' NHS Foundation Trust· Frissítve: 2026. ápr. 29.

  “Recruitment was terminated early by the funder due to study sites' inability to recruit sufficient number of participants.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

  NCT06549296· Nanjing Bioheng Biotech Co., Ltd.· Frissítve: 2026. febr. 3.

  “R\&D strategy adjustment”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study of RD06-04 in Patients With Active Autoimmune Diseases

  NCT06548620· Nanjing Bioheng Biotech Co., Ltd.· Frissítve: 2026. febr. 3.

  “R\&D strategy adjustment”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy

  NCT06462144· The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School· Frissítve: 2026. jan. 28.

  “The collaborating party has adjusted its R\&D strategy and terminated the study.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

  NCT03906227· University of North Carolina, Chapel Hill· Frissítve: 2025. nov. 26.

  “Study recruitment terminated due to lack of funding.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases

  NCT06866080· Nanjing Legend Biotech Co.· Frissítve: 2025. júl. 8.

  “Discontinue further development of LCAR-AIO program”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis

  NCT05168475· Cambridge University Hospitals NHS Foundation Trust· Frissítve: 2025. jún. 17.

  “NIHR withdrawal of funding”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

  NCT06072482· Amgen· Forrás

• Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

  NCT07444567· AstraZeneca· Forrás

• Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

  NCT04157348· AstraZeneca· Forrás

• Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

  NCT07160608· Alexion Pharmaceuticals, Inc.· Forrás

• Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis

  NCT07904806· Otsuka Pharmaceutical Development & Commercialization, Inc.· Forrás

• A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

  NCT06512883· AstraZeneca· Forrás

• Iptacopan in Patients With ANCA Associated Vasculitis

  NCT06388941· Novartis Pharmaceuticals· Forrás

• Qualitative Study With Focus Groups of People Living With ANCA-associated Vasculitis (AAV) and Clinicians, to Explore Different Perspectives on Shared Decision-making in AAV.

  NCT07859995· University of the West of England· Forrás

• CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

  NCT07388277· Marcela V. Maus, M.D.,Ph.D.· Forrás

• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

  NCT06868290· Novartis Pharmaceuticals· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 2
• Mendelian Randomization Analysis 1
• Gene Expression Profiling 8
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 1
• Magnetic Resonance Imaging 14
• Machine Learning 3
• Cohort Studies 16
• Genome-Wide Association Study 3

• Case Report: Eosinophilic granulomatosis with polyangiitis presenting as a multiple sclerosis mimic.

  Front Immunol, 2026. okt.

• Recurrent multiterritorial ischemic stroke with persistent moderate hypereosinophilia: A case report with focused literature review.

  J Int Med Res, 2026. szept.

• [Progressive multifocal leukoencephalopathy associated with rituximab treatment].

  Laeknabladid, 2026. szept.

• Case report: rare progressive cavitary lesion in progressive multifocal leukoencephalopathy.

  J Neurovirol, 2026. júl.

• Anterior ischaemic optic neuropathy as an initial manifestation of eosinophilic granulomatosis with polyangiitis: The importance of early and appropriate immunosuppressive treatment for visual recovery.

  Mod Rheumatol Case Rep, 2026. jún.

• Pituitary involvement in granulomatosis with polyangiitis: a diagnostic and therapeutic challenge.

  Mod Rheumatol Case Rep, 2026. jún.

• ANCA-associated vasculitis with thoracic spinal canal dural involvement and hypertrophic cranial pachymeningitis: A case report.

  Medicine (Baltimore), 2026. máj.

• Eustachian Tube Enhancement Directly Reflects Disease Activity in ANCA-Associated Otitis Media.

  Otol Neurotol, 2026. febr.

• Pituitary involvement in ANCA-associated vasculitis: Case report and literature review.

  Medicine (Baltimore), 2026. jan.

• Subacute parkinsonism associated with proteinuria, hematuria, and PR3-ANCA positivity: a diagnostic challenge.

  BMC Neurol, 2026. jan.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.